Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer

被引：25

作者：

Nowsheen S. ^{[1
]}

Viscuse P.V. ^{[2
]}

O’Sullivan C.C. ^{[3
]}

Sandhu N.P. ^{[4
]}

Haddad T.C. ^{[3
]}

Blaes A. ^{[5
]}

Klemp J. ^{[6
]}

Nhola L. ^{[7
]}

Herrmann J. ^{[8
]}

Ruddy K.J. ^{[3
]}

机构：

[1] Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic School of Medicine and the Mayo Clinic Medical Scientist Training Program, Rochester, MN

[2] Department of Medicine, Mayo Clinic, Rochester, MN

[3] Division of Medical Oncology, Mayo Clinic, 200 First St. SW, Rochester, 55905, MN

[4] Division of General Internal Medicine, Mayo Clinic, Rochester, MN

[5] Department of Medicine, University of Minnesota, Rochester, MN

[6] Division of Clinical Oncology, University of Kansas Medical Center, Wichita, KS

[7] Division of Cardiology Research, Mayo Clinic, Rochester, MN

[8] Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

来源：

Current Breast Cancer Reports | 2017年 / 9卷 / 3期

基金：

美国国家卫生研究院;

关键词：

Breast cancer; Cardio-oncology; Cardiomyopathy; Cardiotoxicity; HER2; Trastuzumab;

D O I：

10.1007/s12609-017-0249-4

中图分类号：

学科分类号：

摘要：

Purpose of Review: Treatment with trastuzumab is a cornerstone of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treatment, but carries an unfortunate risk of toxicity to the cardiovascular system. Here, we review recent findings on trastuzumab-associated cardiotoxicity, focusing on its incidence, diagnosis, and treatment. Recent Findings: Screening with multigated acquisition scan (MUGA) or echocardiogram (ECHO) is recommended to assess cardiac function prior to and during trastuzumab therapy. Because trastuzumab-induced cardiotoxicity is typically reversible, cessation of trastuzumab and/or administration of first-line heart failure agents effectively restores cardiac function in most cases. Severe trastuzumab-induced cardiotoxicity is rare enough that the risk-benefit ratio still weighs in favor of its use in the vast majority of patients with HER2+ breast cancer. Summary: An improved understanding of the pathophysiology underlying trastuzumab-induced cardiotoxicity and the identification of patients at highest risk will allow us to continue to safely administer trastuzumab in patients with breast cancer. © 2017, Springer Science+Business Media, LLC.

引用

页码：173 / 182

页数：9